Saroglitazar

Primary biliary cholangitis

Manufacturer: Zydus Therapeutics
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in April 2027, the start of Zydus fiscal year 2028
Last updated: September 19, 2026

Section

Economic information and modeling report Budget impact model

Epidemiology and eligible population inputs

1 evidence topic · 1 source

UDCA-response population

“refractory or intolerant” (opens the source at this quote in a new tab)

National population estimate and modeled cohort size

No evidence found.